MVA-BN疫苗有效性:疫情背景下真实世界证据的系统综述
本系统综述检索2022年1月1日至2024年2月28日发表的观察性研究,评估MVA-BN疫苗对猴痘的疫苗有效性(VE)。共纳入16条记录,研究设计、背景和高危人群定义存在异质性。在暴露前预防接种人群中,一剂调整后VE为35%至86%(n=8项研究),两剂为66%至90%(n=5项研究);仅暴露后预防接种时,一剂调整后VE为78%和89%(n=2项研究)。
要点
- 暴露前预防接种一剂MVA-BN的调整后VE为35%至86%(n=8项研究)。
- 暴露前预防接种两剂MVA-BN的调整后VE为66%至90%(n=5项研究)。
- 仅暴露后预防接种一剂MVA-BN的调整后VE为78%和89%(n=2项研究)。
核心结论
- 尽管研究设计、背景和高危人群存在异质性,所报告的针对猴痘感染的VE估计值证明了一剂或两剂MVA-BN在多个国家疫情背景下的有效性。
研究设计与样本
- 系统文献综述,检索Medline(通过PubMed)、Embase、LILACS、灰色文献来源及出版物参考文献,纳入2022年1月1日至2024年2月28日发表的观察性研究,共16条记录符合纳入标准,研究均在高收入国家开展,设计、背景和高危人群定义存在异质性,使用NHLBI/NIH质量评估工具评价方法学质量。
主要发现
- 在暴露前预防接种人群中,一剂MVA-BN的调整后VE为35%至86%(n=8项研究),两剂为66%至90%(n=5项研究)。
- 在仅评估暴露后预防接种的研究中,一剂MVA-BN的调整后VE为78%和89%(n=2项研究)。
- 一项研究显示MVA-BN降低猴痘相关住院风险,两项研究显示MVA-BN降低猴痘临床表现的严重程度。
关键数值与推荐
- 暴露前预防接种一剂MVA-BN的调整后VE范围为35%至86%(n=8项研究)。
- 暴露前预防接种两剂MVA-BN的调整后VE范围为66%至90%(n=5项研究)。
- 仅暴露后预防接种一剂MVA-BN的调整后VE为78%和89%(n=2项研究)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究设计、背景和高危人群定义存在异质性。
- 研究均在高收入国家开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mpox is a disease endemic to Central and West Africa. It caused outbreaks in non-endemic countries, mainly in 2022. The endemic Democratic Republic of Congo is currently experiencing its largest outbreak yet. The vaccine Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) is approved for active immunization against mpox and smallpox. Since the outbreak in 2022, real-world studies have assessed MVA-BN's vaccine effectiveness (VE) against mpox, and this systematic literature review aims to summarize the most current evidence. METHODS: Medline (via PubMed), Embase, and LILACS were searched, as well as grey literature sources and publications' bibliographies to identify observational studies published between 1/Jan/2022 and 28/Feb/2024 that estimate the VE of MVA-BN against mpox or provide risk measures that allow calculation of these VE estimates. Data were presented descriptively in tables and text; the methodological quality of included records was assessed using NHLBI/NIH quality assessment tools. RESULTS: The literature search identified 16 records that fit the inclusion criteria. The studies took place in high-income countries and were heterogeneous in design, setting, and definition of at-risk populations. MVA-BN VE estimates against mpox infection were assessed. Where the study population was exclusively or primarily those receiving pre-exposure prophylactic vaccination, the adjusted VE estimates ranged from 35 % to 86 % (n = 8 studies) for one dose and from 66 % to 90 % (n = 5) for two doses. Where only post-exposure prophylactic vaccination was assessed, adjusted VE estimates were reported for one dose only at 78 % and 89 % (n = 2). Additionally, MVA-BN reduced the risk of mpox-related hospitalization in one study and the severity of mpox clinical manifestations in two studies. CONCLUSIONS: Despite heterogeneity in study design, setting, and at-risk populations, the reported VE estimates against mpox infection demonstrated the effectiveness of one or two doses of MVA-BN in the context of an outbreak across multiple countries.
引用
- Mason LMK, Betancur E, Riera-Montes M, et al. MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings. Vaccine. 2024. PMID: 39413490. doi:10.1016/j.vaccine.2024.126409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。